drugset
drugset / Trial / NCT03993873

Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

NCT03993873 ↗

Phase 1 Active not recruiting 95 enrolled Turning Point Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

A phase 1/2, first-in-human, open-label study of the safety, tolerability, PK, and efficacy of the novel MET/CSF1R/SRC inhibitor TPX-0022 in adult subjects with advanced or metastatic NSCLC, Gastric Cancer, or solid tumors harboring genetic alterations in MET. (SHIELD-I)

Timeline

Start
2019-09-05
Primary completion
2024-01-08
Completion
2027-03-03

Drugs

EvaluationDrugModalityDoseRoute
Subject elzovantinib Small molecule — Oral

Indications

metastatic neoplasm neoplasm